Preliminary Agenda
WEDNESDAY, OCTOBER 29, 2025
Chair: Ernesto Guccione, USA
09:05 – 09:30 |Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for
high-throughput quantification of NATs’ functional delivery and potency
Ernesto Guccione
Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, USA
Modeling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids
Ronit Satchi-Fainaro
Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting
Initiative, TAU, IL
DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics
Yaniv Erlich
CEO and Co-Founder, Eleven Therapeutics, IL
Improved Delivery of RNAs for Extra-Hepatic Delivery
Ruben Postel
CSO & Scientific Founder, Sapreme Technologies, The Netherlands
Utilizing Machine Learning to Unlock RNA Delivery
Yogev Debbi
Co-Founder & CEO, Mana.bio, IL
Session 2: RNA Splicing Mechanisms in Cancer
Chair
Claudio Sette, Italy
SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer
Adrian Krainer
St. Giles Foundation Professor, Cold Spring Harbor Laboratory, New York, USA
Splicing dysregulation: Hallmark and therapeutic opportunity in cancer
Claudio Sette
Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy
Pseudoexon activation as a therapeutic approach
Brage Storstein Andresen
Head of Research, Brage Storstein Andresen Lab, University of Southern Denmark
Start-Up Presentation
Programmable multi-kilobase RNA editing with splice editors
Jacob Borrajo
Chief Executive Officer & Co-Founder, Amber Bio, USA
Start-Up Presentation
Peter D. Weinstein
Chief Executive Officer/General Counsel, Emervax Inc., USA
Session 3: Novel Therapeutic Applications of RNA Technology: Part 1
Chair
Michal Lotem, IL
Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia
Marcin Kortylewski
Principal Investigator, The Kortylewski Lab, City of Hope, USA
Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder
Christopher Ricupero
Assistant Professor, Columbia University Irving Medical Center, USA
Working with patient communities to develop ASO based therapies
Yael Weiss
Founder & CEO, Mahzi Therapeutics, USA
Selected Talk
Session 4: Novel Therapeutic Applications of RNA Technology: Part 2
Chair: Michal Lotem
Developing RNA based approaches for the treatment of Pompe Disease and
neurodegenerative conditions
Emanuele Buratti
Group Leader, Molecular Pathology Lab, ICGEB, Italy
Start-Up Presentation
A transformative RNA (ASOs) based company for the treatment of pulmonary diseases
Gili Hart
CEO, SpliSense, IL
Start-Up Presentation
Enabling Precision Medicine: From Liquid Biopsy to Antigen Discovery with Next-Gen Technologies
Massimiliano Clamer
Chairman & Founder, Immagina Biotechnology, Italy
Industry Panel Discussion: Shaping the Future of RNA Therapeutics:
Innovation, Investment, and Impact
Panelists:
Yael Gruenbaum Cohen, aMoon Alpha, IL
Michelle Lynn Hall, Associate Vice President, Eli Lilly and Company, USA
Yaniv Erlich, CEO and Co-Founder, Eleven Therapeutics, IL
Yael Weiss, Founder & CEO, Mahzi Therapeutics, USA
Tamar Grossman,
CEO, La Jolla Labs, USA
Poster Session
THURSDAY, OCTOBER 30, 2025
Session 5: Novel Therapeutic Applications of RNA Technology: Part 3
Chair: Ernesto Guccione, USA
Opening Remarks
Targeting noncoding elements to boost haploinsufficient gene expression
Igor Ulitsky
Principal Investigator, Ulitsky Lab, Weizmann Institute of Science, IL
Small and long non-coding RNA transforming cell fates in the brain
Anna Krichevsky
Brigham and Women’s Hospital, and Harvard Medical School, USA
Exploiting the dark genome to target drug-tolerant cells and improve anticancer
immune therapies
Eleonora Leucci
Principal Investigator – RNA Cancer Biology Lab, KU Leuven, Belgium
Targeted delivery of therapeutic oligonucleotides for the treatment of neuromuscular
diseases
Oxana Beskrovnaya
Chief Innovation Officer, Dyne Therapeutics, USA
Start-Up Presentation
Cell-free RNA as a Mediator of Inflammation: New Paradigms for Therapeutic
Intervention
James Posada
Chief Executive Officer, Resolve Therapeutics, USA
Start-Up Presentation
Bispecific siRNA to reduce Cardiometabolic Risk
Michael Khan
Chief Executive Officer, Argonaute RNA, UK
Start-Up Presentation
Targeting miR-22 with an Antisense Oligonucleotide: a new RNA-based paradigm
for treating obesity
Riccardo Panella, Chief Scientific Officer, Resalis Therapeutics, Italy
Coffee Break, Visit the Exhibition & Poster Viewing
Session 6: Innovations in Tumor Targeting and Cancer Immunotherapy
Using RNA
Chair: Rotem Karni, IL / USA
Opening Remarks
Rewriting the Message: RNA Splice Disruption Unmasks New Cancer
Immunotherapy Targets
Michal Lotem
Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew
University Medical Center, IL
Aberrantly spliced cancer proteoforms: If you can’t beat them, eat them!
Andrei Thomas-Tikhonenko
Director of Experimental Pathology, Children’s Hospital of Philadelphia, USA
Targeting RNA processing to induce neoantigen in cancer cells
Rotem Karni
Principal Investigator, Hebrew University-Hadassah Medical School, IL and
University of Pennsylvania, USA
Selected Talk
A novel regulatory circuit required for tumor angiogenesis and cancer growth
Claudia Ghigna
Scientist, Institute of Molecular Genetics, Italy
Selected Talk
Lunch Break, Visit the Exhibition & Poster Viewing
Session 7: RNA Regulation & Translation in Cancer Biology
Chair: Claudio Sette, Italy
Opening Remarks
RNA-binding proteins in melanoma progression
Fátima Gebauer
President of the RNA Society and Principal Investigator, Center for Genomic
Regulation (CRG), Spain
Exploiting RNA translation control to fight cancer resistance
Caroline Robert
Head of Dermatology, Gustave Roussy Institute, France
Ultra-conserved poison exons in SR protein splicing regulator genes: Do these
operate as tumour suppressors or protect the functions of specific cell types?
David Elliott
Principal Investigator, Newcastle University, UK
Coffee Break, Visit the Exhibition & Poster Viewing
Session 8: RNA Regulation & Translation in Cancer Biology (cont.)
Chair: Claudio Sette, Italy
Start-Up Presentation
Targeting m6A-RNA Biology IN FTO-Dependent Cancers
Amir Mor
CSO, RNAble, IL
Breast cancer transcriptomics at the bulk, single cell and spatial levels
Carlos Caldas
Honorary Consultant in Medical Oncology, University of Cambridge, UK
Session 9: Computational & AI Applications in RNA Therapeutics
Chair: Rotem Karni, IL / USA
Opening Remarks
AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics
Tamar Grossman
CEO, La Jolla Labs, USA
miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer
cell classification
Ron Weiss
Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology,
USA
Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy
Aron Popovtzer
Director of the Sharett Institute of Oncology, Hadassah Medical Center, IL
Coffee Break, Visit the Exhibition & Poster Viewing
Session 10: Computational & AI Applications in RNA Therapeutics (cont.)
Chair: Rotem Karni, IL / USA
Decoding Cancer Complexity: Machine Learning and Transcriptomic Signatures
Shai Rosenberg
Head of the Computational Medicine Service, Hadassah Hebrew University
Medical Center, IL
Concluding Remarks and Symposium Closure
Lunch
